Thioctic acid for patients with symptomatic diabetic polyneuropathy: A critical review

Treatments in Endocrinology

Volumn 3, Issue 3, 2004, Pages 173-189

  Ziegler, Dan ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALBUMIN; FREE RADICAL; GLIBENCLAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXYNITRITE; PLACEBO; SUPEROXIDE; THIAMINE; THIOCTIC ACID; THROMBOMODULIN; VITAMIN B GROUP;

ABDOMINAL PAIN; AGITATION; ANAPHYLAXIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE SEVERITY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GLUCOSE OXIDATION; GLUCOSE UTILIZATION; HEADACHE; HOT FLUSH; HUMAN; HYPERHIDROSIS; LARYNX SPASM; MAJOR CLINICAL STUDY; META ANALYSIS; MICROCIRCULATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PHARMACODYNAMICS; POLYNEUROPATHY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; QUALITY OF LIFE; REVIEW; SCIATIC NERVE; SIDE EFFECT; SLEEP DISORDER; URTICARIA; VOMITING;

ANIMALS; ANTIOXIDANTS; DIABETIC NEUROPATHIES; HUMANS; THIOCTIC ACID;

EID: 2642548826     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200403030-00005     Document Type: Review

References (129)

1. American Diabetes Association, American Academy of Neurology. Consenus statement: report and recommendations of the San Antonio conference on diabetic neuropathy. Diabetes Care 1988; 11: 592-7
2. Thomas PK. Metabolic neuropathy. J R Coll Physicians Lond 1973; 7: 154-60
3. Shaw JE, Zimmet PZ, Gries FA, et al. Epidemiology of diabetic neuropathy. In: Gries FA, Cameron NE, Low PA, et al., editors. Textbook of diabetic neuropathy. New York: Thieme Stuttgart, 2003: 64-82
4. Resnick HE, Vinik AI, Schwartz AV, et al. Independent effects of peripheral nerve dysfunction on lower-extremity physical function in old age: The Women's Health and Aging study. Diabetes Care 2000; 23: 1642-7
5. Forsblom CM, Sane T, Groop P-H, et al. Risk factors for mortality in type 2 (non-insulin-dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4. Diabetologia 1998; 41: 1253-62
6. Coppini DV, Bowtell PA, Weng C, et al. Showing neuropathy is related to increased mortality in diabetic patients: a survival analysis using an accelerated failure time model. J Clin Epidemiol 2000; 53: 519-23
7. Abbott CA, Vileikyte L, Williamson S, et al. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 1998; 21: 1071-5
8. Chan AW, MacFarlane IA, Bowsher D, et al. Chronic pain in patients with diabetes mellitus: comparison with non-diabetic population. The Pain Clinic 1990; 3: 147-59
9. Galer BS, Gianas A, Jensen MP. Painful diabetic neuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000; 47: 123-8
10. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-53
12. Pfeifer MA, Schumer MP. Clinical trials of diabetic neuropathy: past, present, and future. Diabetes 1995; 44: 1355-61
13. Ziegler D. Glycemic control. In: Gries FA, Cameron NE, Low PA, et al., editors. Textbook of diabetic neuropathy. New York: Thieme Stuttgart, 2003: 91-6
14. Cameron NE, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997; 46 Suppl. 2: S31-7
15. Tomlinson DR, Fernyhough P, Diemel LT. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors. Diabetes 1997; 46 Suppl.2 S43-9
16. Pfeifer MA, Schumer MP, Gelber DA. Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes 1997; 46 Suppl.2: S82-9
17. Horrobin DF. Essential fatty acids in the management of impaired nerve function in diabetes. Diabetes 1997; 46 Suppl. 2: S38-42
18. Low PA, Nickander KK, Tritschler HJ. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 1997; 46 Suppl. 2: S38-42
19. Tütüncü NB, Bayraktar M, Varli K. Reversal of defective nerve conduction with vitamin E supplementation in type 2 diabetes. Diabetes Care 1998; 21: 1915-8
20. Malik RA, Williamson S, Abbott C, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomized double-blind controlled trial. Lancet 1998; 352: 1978-81
21. Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular complications. Diabetic Med 2001; 18: 945-59
22. Apfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy. JAMA 2000; 284: 2215-21
23. Nicolucci A, Carinci F, Cavaliere D, et al. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. Diabet Med 1996; 13: 1017-26
24. Cavaliere D, Scorpiglione N, Belfiglio M, et al. Quality assessment of randomised clinical trials on medical treatment of diabetic neuropathy. Diabetes Nutr Metab 1994; 7: 287-94
25. Luft D, Ziegler D. Evaluation of drug effects. In: Gries FA, Cameron NE, Low PA, et al., editors. Textbook of diabetic neuropathy. New York: Thieme Stuttgart, 2003: 313-60
26. Nicolucci A, Carinci F, Graepel JG, et al. The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy: a meta-analysis of individual patient data. Diabetes Care 1996; 19: 1091-6
27. Ziegler D. Treatment of neuropathic pain. In: Gries FA, Cameron NE, Low PA, et al., editors. Textbook of diabetic neuropathy. New York: Thieme Stuttgart, 2003: 211-24
28. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-12
29. Ziegler D, Sohr C, Akila F, et al. Oxidative stress in diabetic patients with or without polyneuropathy and cardiovascular autonomic neuropathy [abstract]. Diabetologia 2002; 45 Suppl. 2: A329
30. Suzuki YJ, Tsuchiya M, Packer L. Thioctic acid and dihydrolipoic acid are novel antioxidants which interact with reactive oxygen species. Free Radic Res Commun 1991; 15: 255-63
31. Packer L, Witt EH, Tritschler H. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med 1995; 19: 227-50
32. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20
33. Packer L, Krämer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetic complications. Nutrition 2001; 17: 888-95
34. Haramaki N, Han D, Handelmann DL, et al. Cytosolic and mitochondrial systems for NADH- and NADPH-dependent reduction of alpha-lipoic acid. Free Radic Biol Med 1997; 22: 535-42
35. Nagamatsu M, Nickander KK, Schmelzer JD, et al. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995; 18: 1160-7
36. Nickander KK, McPhee BR, Low PA, et al. Alpha-lipoic acid: antioxidant potency against lipid peroxidation of neural tissues in vitro and implications for diabetic neuropathy. Free Radic Biol Med 1996; 21: 631-9
37. Bierhaus A, Chevion S, Chevion M, et al. Advanced glycation end product-induced activation of NF-κB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 1997; 46: 1481-90
38. Garret NE, Malcangio M, Dewhurst M, et al. Alpha-lipoic acid corrects neuropeptide deficits in diabetic rats via introduction of trophic support. Neurosci Lett 1997; 222: 191-4
39. Mitsui Y, Schmelzer JD, Zollman PJ, et al. Alpha-lipoic acid provides neuroprotection from ischemia-reperfusion injury of peripheral nerve. J Neurol Sci 1999; 163: 11-6
40. Stevens MJ, Obrosova I, Cao X, et al. Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 2000; 49: 1006-15
41. Cameron NE, Jack AM, Cotter MA. Effect of alpha-lipoic acid on vascular responses and nociception in diabetic rats. Free Radic Biol Med 2001; 31: 125-35
42. Coppey LJ, Gellett JS, Davidson EP, et al. Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 2001; 50: 1927-37
43. Piotrowski P, Wierzbicka K, Smialek M. Neuronal death in the rat hippocampus in experimental diabetes and cerebral ischaemia treated with antioxidants. Folia Neuropathol 2001; 39: 147-54
44. Kunt T, Forst T, Wilhelm A, et al. Alpha-lipoic acid reduces expression of vascular cell adhesion molecule-1 and endothelial adhesion of human monocytes after stimulation with advanced glycation end products. Clin Sci (Lond) 1999; 96: 75-82
45. Kocak G, Aktan F, Canbolat O, et al. The ADIC Study Group: antioxidants in diabetes-induced complications: alpha-lipoic acid treatment ameliorates metabolic parameters, blood pressure, vascular reactivity and morphology of vessels already damaged by streptozotocin-diabetes. Diabetes Nutr Metab 2000; 13: 308-18
46. Jain SK, Lim G. Lipoic acid decreases lipid peroxidation and protein glycosylation and increases (Na(+) + K(+))- and Ca(++)-ATPase activities in high glucose-treated human erythrocytes. Free Radic Biol Med 2000; 29: 1122-8
47. 2 by alpha-lipoic acid mediates the recovery of basal EDRF/NO availability and the reversal of superoxide dismutase-induced relaxation in diabetic rat aorta. Diabetes Obes Metab 2002; 4: 69-74
48. Melhem MF, Craven PA, Derubertis FR. Effects of dietary supplementation of alpha-lipoic acid on early glomerular injury in diabetes mellitus. J Am Soc Nephrol 2001; 12: 124-33
49. Melhem MF, Craven PA, Liachenko J, et al. Alpha-lipoic acid attenuates hyperglycemia and prevents glomerular mesangial matrix expansion in diabetes. J Am Soc Nephrol 2002; 13: 108-16
50. Visioli F, Smith A, Zhang W, et al. Lipoic acid and vitamin C potentiate nitric oxide synthesis in human aortic endothelial cells independently of cellular glutathione status. Redox Rep 2002; 7: 223-7
51. El Midaoui A, de Champlain J. Prevention of hypertension, insulin resistance, and oxidative stress by alpha-lipoic acid. Hypertension 2002; 39: 303-7
52. Shotton HR, Clarke S, Lincoln J. The effectiveness of treatments of diabetic autonomic neuropathy is not the same in autonomic nerves supplying different organs. Diabetes 2003; 52: 157-64
53. Stockklauser-Farber K, Ballhausen T, Laufer A, et al. Influence of diabetes on cardiac nitric oxide synthase expression and activity. Biochim Biophys Acta 2000; 1535: 10-20
54. Strödter D, Lehmann E, Lehmann U, et al. The influence of thioctic acid on metabolism and function of the diabetic heart. Diabetes Res Clin Pract 1995; 29: 19-26
55. Ramrath S, Tritschler HJ, Eckel J. Stimulation of cardiac glucose transport by thioctic acid and insulin. Horm Metab Res 1999; 31: 632-5
56. Obrosova I, Cao X, Greene DA, et al. Diabetes-induced changes in lens antioxidant status, glucose utilization and energy metabolism: effect of DL-α-lipoic acid. Diabetologia 1998; 41: 1442-50
57. Obrosova IG, Minchenko AG, Marinescu V, et al. Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia 2001; 44: 1102-10
58. Borenshtein D, Ofri R, Werman M, et al. Cataract development in diabetic sand rats treated with alpha-lipoic acid and its gamma-linolenic acid conjugate. Diabetes Metab Res Rev 2001; 17: 44-50
59. Goralska M, Dackor R, Holley B, et al. Alpha-lipoic acid changes iron uptake and storage in lens epithelial cells. Exp Eye Res 2003; 76: 241-8
60. Persson HL, Svensson AI, Brunk UT. Alpha-lipoic acid and alpha-lipoamide prevent oxidant-induced lysosomal rupture and apoptosis. Redox Rep 2001; 6: 327-34
61. Myzak MC, Carr AC. Myeloperoxidase-dependent caspase-3 activation and apoptosis in HL-60 cells: protection by the antioxidants ascorbate and (dihydro)lipoic acid. Redox Rep 2002; 7: 47-53
62. Anderwald C, Koca G, Furnsinn C, et al. Inhibition of glucose production and stimulation of bile flow by R(+)-alpha-lipoic acid enantiomer in rat liver. Liver 2002; 22: 355-62
63. Liu J, Head E, Gharib AM, et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha-lipoic acid. Proc Natl Acad Sci U S A 2002; 99: 2356-61
64. Liu J, Killilea DW, Ames BN. Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L-carnitine and/or R-alpha-lipoic acid. Proc Natl Acad Sci U S A 2002; 99: 1876-81
65. Hagen TM, Liu J, Lykkesfeldt J, et al. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci U S A 2002; 99: 1870-5
66. Hermann R, Niebch G, Borbe HO, et al. Enantioselective pharmacokinetics and bioavailability of different racemic α-lipoic acid formulations in healthy volunteers. Eur J Pharm Sci 1996; 4: 167-74
67. Rosak C, Ziegler D, Mehnert H, et al. Lokale Verträglichkeit intravenöser α-Liponsäure. Munch Med Wochenschr 1994; 136: 142-6
68. Gleiter CH, Schug BS, Hermann R, et al. Influence of food intake on the bioavailability of thioctic acid enantiomers. Eur J Clin Pharmacol 1996; 509: 513-4
69. Gleiter CH, Schreeb KH, Freudenthaler S, et al. Lack of interaction between thioctic acid, glibenclamide and acarbose. Br J Clin Pharmacol 1999; 48: 819-25
70. Ruus P, Eggenstein C, Niebch G, et al. Pharmacokinetics of thioctic acid, glibenclamide and acarbose. Br J Clin Pharmacol 1999; 48: 819-25
71. Peter G, Borbe HO. Untersuchungen zur Absorption und Verteilung der Thioctsäure als Grundlage der klinischen Wirksamkeit bei Behandlung der diabetischen polyneuropathie. Diabetes Stoffwechsel 1996; 5: 12-6
72. Biewenga G, Vriesmann MF, Haenen GRMM, et al. The identification of a new metabolite of lipoic acid in man: 3-ketolipoic acid. In: Thesis G, editor. Biewenga: lipoic acid: a pharmacochemical study. Netherlands: Vrije Universiteit Amsterdam, 1997: 137-52
73. Locher M, Busker E, Borbe HO. Metabolism of α-lipoic acid in human volunteers [abstract 206]. Naunyn Schmiederbergs Arch Pharmacol 1995; R52: 351
74. Stevens JL, Bakke JE. S-methylation. In: Mulder GJ, editor. Conjugation reactions in drug metabolism. London: Taylor and Francis, 1990
75. Haak ES, Usadel KH, Kohleisen M, et al. The effect of α-lipoic acid on the neurovascular reflex arc in patients with diabetic neuropathy assessed by capillary microscopy. Microvasc Res 1999; 58: 28-34
76. Kusterer K, Haak E, Haak T. Lipoate prevention of diabetic microangiopathy. In: Fuchs J, Packer L, Zimmer G, editors. Lipoic acid in health and disease. New York: Marcel Decker, 1997: 429-34
77. Haak E, Usadel KH, Kusterer K, et al. Effects of alpha-lipoic acid on microcirculation in patients with peripheral diabetic neuropathy. Exp Clin Endocrinol Diabetes 2000; 108: 168-74
78. Hofmann M, Zimmer G. Lipoate prevention of diabetic microangiopathy. In: Fuchs J, Packer L, Zimmer G, editors. Lipoic acid in health and disease. New York: Marcel Decker, 1997: 423-7
79. Borcea V, Nourooz-Zadeh J, Wolff SP, et al. Alpha-lipoic acid decreases oxidative stress in patients with diabetes mellitus. Free Radic Biol Med 1999; 22: 1495-500
80. Heitzer T, Finckh B, Albers S, et al. Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med 2001; 31: 53-61
81. Strokov IA, Manukhina EB, Bakhtina LY, et al. The function of endogenous protective systems in patients with insulin-dependent diabetes mellitus and polyneuropathy: effect of antioxidant therapy. Bull Exp Biol Med 2000; 130: 986-90
82. Androne L, Gavan NA, Veresiu IA, et al. In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy. In Vivo 2000; 14: 327-30
83. Kähler W, Kuklinski B, Rühlmann C, et al. Diabetes mellitus: eine mit freien radikalen assoziierte erkrankung. Inn Med 1993; 48: 223-32
84. Hofmann MA, Bierhaus A, Zumbach MS, et al. Insufficient glycemic control increases nuclear factor-κB binding activity in peripheral blood mononuclear cells isolated from patients with type I diabetes. Diabetes Care 1998; 21: 1310-6
85. Hofmann MA, Schiekofer S, Isermann B, et al. Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-κB. Diabetologia 1999; 42 (2): 222-32
86. Morcos M, Borcea V, Isermann B, et al. Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diabetes Res Clin Pract 2001; 52: 175-83
87. Dyck PJ, Davies JL, Wilson DM, et al. Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 1999; 22: 1479-86
88. Kishi Y, Schmelzer JD, Yao JK, et al. Lipoic acid: effect on glucose uptake, sorbitol pathway and energy metabolism in experimental diabetic neuropathy. Diabetes 1999; 48: 2045-51
89. Jacob S, Henriksen EJ, Tritschler HJ, et al. Enhancement of glucose disposal in patients with type 2 diabetes by α-lipoic acid. Arzneimittel Forschung 1995; 45: 872-4
90. Jacob S, Henriksen EJ, Tritschler HJ, et al. Improvement of insulin-stimulated glucose-disposal in type 2 diabetes after repeated parenteral administration of thioctic acid. Exp Clin Endocrinol Diabetes 1996; 104: 284-8
91. Rett K, Wickmayr M, Ruus P, et al. α-Liponsäure steigert die Insulinempfindlichkeit übergewichtiger Patienten mit typ II Diabetes. Diabetes und Stoffwechsel 1996; 5 (3 Suppl.): 59-63
92. Jacob S, Rett K, Henricksen EJ, et al. Thioctic acid: effect on insulin sensitivity and glucose-metabolism. Biofactors 1999; 10: 169-74
93. Evans JL, Goldfine ID. Alpha-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. Diabetes Technol Ther 2000; 2: 401-13
94. Jacob S, Ruus P, Hermann R, et al. Oral administration of rac-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med 1999; 27: 309-14
95. Konrad T, Vicini P, Kusterer K, et al. α-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care 1999; 22: 280-7
96. Evans OB. Pyruvate decarboxylase deficiency in subacute necrotizing encephalomyelopathy. Arch Neurol 1981; 38: 515-9
97. Barbiroli B, Medori R, Tritschler HJ, et al. Lipoic (thioctic) acid increases brain energy availability and skeletal muscle performance as shown by in vivo 31P MRS in a patient with mitochondrial cytopathy. J Neurol 1995; 242: 472-7
98. Grover WD, Auerbach VH, Patel MS. Biochemical studies and therapy in subacute encephalomyelopathy (Leigh's syndrome). J Pediatrics 1972; 81 (1 Suppl.): 39-44
99. Hommes FA, Polman HA, Reerink JD. Leigh's encephalomyelopathy: an inborn error of gluconeogenesis. Arch Dis Child 1968; 43: 423-6
100. Haworth JC, Perry TL, Blass JP, et al. Lactic acidosis in three sibs due to defects in both pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenases complexes. Pediatrics 1976; 58: 564-72
101. Maesaka H, Komiya K, Misugi K, et al. Hyperalaninemia, hyperpyruviemia and lactic acidosis due to pyruvate carboxylase deficiency of the liver; treatment with thiamine and lipoic acid. Eur J Pediatr 1976; 122: 159-68
102. Matalon R, Stumpf DA, Michals K, et al. Lipoamide dehydrogenase deficiency with primary lactic acidosis: favorable response to treatment with oral lipoic acid. Journal of Pediatrics 1984; 104 (1 Suppl.): 65-9
103. Robinson BH, Taylor J, Sherwood WG. Deficiency of dihydrolipoyl dehydrogenase (a component of pyruvate and α-ketoglutarate dehydrogenase complexes): a cause of congenital chronic lactic acidosis in infancy. Pediatr Res 1977; 11: 1198-202
104. Clayton BE, Dobbs RH, Patrick AD. Leigh's subacute necrotizing encephalopathy: clinical and biochemical study, with special reference to therapy with lipoate. Arch Dis Child 1967; 42: 467-78
105. Barbiroli B, Medori R, Tritschler HJ, et al. Thioctic acid stimulates muscle ATP production in patients with type II diabetes and diabetic polyneuropathy. Diabetes und Stoffwechsel 1996; 5 (3 Suppl.): 71-6
106. Bock E, Schneeweiss J. Ein Beitrag zur Therapie der Neuropathia diabetica. Munch Med Wochenschr 1959; 43: 1911-2
107. Sachse G, Willms B. Efficacy of thioctic acid in the therapy of peripheral diabetic neuropathy. Horm Metab Res 1980; 9: 105-8
108. Schulz B, Reichel G, Hüttie I, et al. Zur Wirksamkeit der Thioctsäuretherapie bei Typ-I-Diabetikern. Wiss Z Ernst-Moritz-Arndt-Univ. Greifswald 1986; 35: 48-50
109. Jörg J, Metz F, Scharafinski H. Zur medikamentösen Behandlung der diabetischen Polyneuropathie mit der α-Liponsäure oder Vitamin B-Präparaten. Nervenarzt 1988; 9: 36-44
110. Delcker A, Fischer PA, Ulrich H. Randomisierte Studie Thioctsäure gegenüber Vitamin-B-kombinationspräparat bei Patienten mit diabetischer Polyneuropathie unter besonderer Berücksichtigung des peripheren Nervensystems. In: Borbe HO, Ulrich O, editors. Thioctsäure: Neue biochemische, pharmakologische und klinische Erkenntnisse zur Thioctsäure. Frankfurt: pmi Verlag, 1989: 335-49
111. Reschke B, Zeuzem S, Rosak C, et al. Hochdosierte Langzeitbehandlung mit Thioctsäure bei der diabetischen Polyneuropathie: Ergebnisse einer kontrollierten, randomisierten Studie unter besonderer Berücksichtigung der autonomen Neuropathie. In: Borbe HO, Ulrich H, editors. Thioctsäure: Neue biochemische, pharmakologische und klinische Erkenntnisse zur Thioctsäure. Frankfurt: pmi Verlag, 1989: 318-34
112. Ziegler D, Mayer P, Mühlen H, et al. Effekte einer Therapie mit α-Liponsäure gegenüber Vitamin B1 bei der diabetischen Neuropathie. Diab Stoffw 1993; 2: 443-8
113. Strokov IA, Kozlova NA, Mozolevsky YuV, et al. Efficacy of IV-administration of trometamol salt of thioctic (α-lipoic) acid in diabetic neuropathy. J Neurol Psychiatry 1999; 6: 18-22
114. Schreiber FK. Zur Behandlung der Neuropathia diabetica. Dtsch Med Wochenschr 1961; 86: 531-6
115. Klein W. Die Behandlung der Neuropathia diabetica mit oralen Gaben von α-Liponsäure. Munchner Med Wochenschr 1975; 22: 957-8
116. Peripheral Nerve Society. Diabetic polyneuropathy in controlled clinical trials: consensus report of the Peripheral Nerve Society. Ann Neurol 1995; 38: 478-82
117. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant α-lipoic acid: a 3-week multicentre randomized controlled trial (ALADIN study). Diabetologia 1995; 38: 1425-33
118. Young MJ, Boulton AJM, Macleod AF, et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 150-4
119. Dyck PJ, Davies JL, Litchy WJ, et al. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997; 49: 229-39
120. Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (α-lipoic acid): a two-year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radic Res 1999; 31: 171-9
121. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III study). Diabetes Care 1999; 22: 1296-301
122. Ziegler D, Schatz H, Conrad F, et al. Effects of treatment with the antioxidant α-lipoic acid on cardiac autonomic neuropathy in NIDDM patients: a 4-month randomized controlled multicenter trial (DEKAN Study). Diabetes Care 1997; 20: 369-73
123. Ruhnau K-J, Meissner HP, Finn JR, et al. Effects of 3-week oral treatment with the antioxidant, thioctic acid (α-lipoic acid), in symptomatic diabetic polyneuropathy. Diabetic Med 1999; 16: 1040-3
124. Ametov A, Barinov A, O'Brien P, et al. The sensory symptoms of diabetic polyneuropathy are improved with α-lipoic acid: the SYDNEY trial. Diabetes Care 2003; 26: 770-6
125. Dyck PJ, O'Brien PC. Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy. Diabetes Care 1989; 12: 649-52
126. Rathmann W, Haastert B, Delling B, et al. Postmarketing surveillance of adverse drug reactions: a correlation study approach using multiple data sources. Pharmacoepiemiol Drug Saf 1998; 7: 51-7
127. Ziegler D. Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and treatment. Diabetes Metab Rev 1994; 10: 339-83
128. Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a meta-analysis. Diabetic Med 2004; 21: 114-21
129. Data on file, VIATRIS GmbH, 2003